Open-Label Psilocybin Study
Phase 1
50
about 3.2 years
18+
1 site in CT
About this study
Researchers are testing the safety of psilocybin in people with mental health symptoms. The trial will last 1170 days and involve giving participants a single dose of psilocybin, followed by follow-up visits at different times.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Psilocybin
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
oral
Primary: Adverse Events Log, Columbia-Suicide Severity Rating Scale (C-SSRS)
Secondary: Beck Depression Inventory (BDI-II), Brief Symptom Inventory (BSI), Hamilton Anxiety Rating Scale (HAM-A), Inventory for Depression and Anxiety Symptoms (IDAS-II), Montgomery-Asberg Depression Scale (MADRS), Quality of Life Enjoyment & Satisfaction Questionnaire - Short Form (Q-LES-Q-SF), Yale-Brown Obsessive-Compulsive Scale-Second Edition (Y-BOCS-II) Symptom Checklist and Severity Scale
Psychiatry / Mental Health